TG Therapeutics (TGTX) Stock Forecast & Price Target

TG Therapeutics is supported by BRIUMVI’s commercial traction in RMS, with U.S. market share rising to 8% in 1Q26 from 7% and BRIUMVI the only anti-CD20 to grow U.S. revenues sequentially while Ocrevus and Kesimpta declined. The company also has a meaningful operational edge if consolidated IV dosing is approved, since a single-initiation infusion would remove the Day 15 visit and could strengthen payer and infusion-center adoption versus two-infusion competitors. Its outlook is reinforced by ENABLE data showing durable patient-reported benefits through Week 48 and real-world switch outcomes of 99.4% relapse-free with an ARR of 0.011, supporting continued share gains.

TG Therapeutics is dependent on a valuation framework that already assumes generous success odds for Briumvi IV at 100% POS and Briumvi SC at 70% POS, yet still excludes other pipeline assets and indications, implying limited optionality in the core model. The reliance on a 12% discount rate and a -25% terminal growth rate through 2038 signals meaningful long-term uncertainty, while safety, efficacy, regulatory, and IP risks could materially impair commercial execution. This makes the stock vulnerable if Briumvi faces stronger-than-expected competition or any clinical setback, because the investment case rests heavily on one franchise rather than a diversified growth base.